Taken together, these findings suggest that Hs-CRP is closely associated with infection severity, amputation risk, and adverse short-term outcomes in DFU patients, and appears to outperform procalcitonin in diagnostic accuracy. The gene discussed is MAP3K14; the disease is infection.